GlassScriptPhysician profile
Ghaison F Serafini
NPI 1801193644
$8,484.81
in general payments reported to CMS, 2019-2025
48 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 92% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $1,269 · 2021: $2,002 · 2022: $975 · 2023: $1,079 · 2024: $1,275 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,446 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,445.77 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,393.29 | 2019-2025 | Fasenra, Airsupra |
| Lilly USA, LLC | $696.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $599.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $501.40 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $490.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.32 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $455.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $448.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $343.79 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $296.73 | 2020-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $238.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $236.21 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.27 | 2020-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $210.96 | 2024-2025 | Eliquis |
| Corcept Therapeutics | $206.90 | 2023-2024 | Korlym |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghaison Serafini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.